Über das Cytochrom P450-System werden viele verschiedene Arzneimittel metabolisiert. Dies erklärt dass viele Medikamenten Interaktionen und Nebenwirkungen aus Interfrenzen in den gemeinsamen Stoffwechselwegen resultieren.
1. |
Paolini M et al. (1999) Co-carcinogenic effect of beta-carotene. |
2. |
Nebert DW et al. (1987) P450 genes: structure, evolution, and regulation. |
3. |
Daly AK et al. (1992) Deficient nifedipine oxidation: a rare inherited trait associated with cystic fibrosis kindreds. |
4. |
Inoue K et al. (1992) Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization. |
5. |
Wolf CR et al. (1992) Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. |
6. |
Wrighton SA et al. (1992) The human hepatic cytochromes P450 involved in drug metabolism. |
7. |
Forrester LM et al. (1990) Evidence for involvement of multiple forms of cytochrome P-450 in aflatoxin B1 metabolism in human liver. |
8. |
Shimada T et al. (1989) Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. |
9. |
Wrighton SA et al. (1989) Isolation and characterization of human fetal liver cytochrome P450HLp2: a third member of the P450III gene family. |
10. |
Spurr NK et al. (1989) The human cytochrome P450 CYP3 locus: assignment to chromosome 7q22-qter. |
11. |
Brooks BA et al. (1988) The gene CYP3 encoding P450pcn1 (nifedipine oxidase) is tightly linked to the gene COL1A2 encoding collagen type 1 alpha on 7q21-q22.1. |
12. |
Renwick AG et al. (1988) The pharmacokinetics of oral nifedipine--a population study. |
13. |
Gonzalez FJ et al. (1988) Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. |
14. |
Schellens JH et al. (1988) Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. |
15. |
Molowa DT et al. (1986) Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver. |
16. |
Watkins PB et al. (1985) Identification of an inducible form of cytochrome P-450 in human liver. |
17. |
Kleinbloesem CH et al. (1984) Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. |
18. |
Elshourbagy NA et al. (1980) Separation, purification, and characterization of a novel form of hepatic cytochrome P-450 from rats treated with pregnenolone-16 alpha-carbonitrile. |
19. |
Shet MS et al. (1993) Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. |
20. |
Chen H et al. (1996) Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. |
21. |
Lown KS et al. (1997) Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. |
22. |
Thummel KE et al. (1998) In vitro and in vivo drug interactions involving human CYP3A. |
23. |
Rebbeck TR et al. (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. |
24. |
Lehmann JM et al. (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. |
25. |
Felix CA et al. (1998) Association of CYP3A4 genotype with treatment-related leukemia. |
26. |
Paris PL et al. (1999) Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. |
27. |
Goodwin B et al. (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. |
29. |
Xie W et al. (2000) Humanized xenobiotic response in mice expressing nuclear receptor SXR. |
30. |
Kittles RA et al. (2002) CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? |
31. |
Goodwin B et al. (2002) Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. |
32. |
Zeigler-Johnson CM et al. (2002) Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. |
33. |
Tirona RG et al. (2003) The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. |
34. |
Dimaraki EV et al. (2003) Troglitazone induces CYP3A4 activity leading to falsely abnormal dexamethasone suppression test. |
35. |
Masuyama H et al. (2003) Expression and potential roles of pregnane X receptor in endometrial cancer. |
36. |
Markowitz JS et al. (2003) Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. |
37. |
Loukola A et al. (2004) Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2. |
38. |
Gupta RP et al. (2004) CYP3A4 is a human microsomal vitamin D 25-hydroxylase. |
39. |
Williams PA et al. (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. |
40. |
Hirota T et al. (2004) Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status. |
41. |
Gupta RP et al. (2005) CYP3A4 is a vitamin D-24- and 25-hydroxylase: analysis of structure function by site-directed mutagenesis. |
42. |
Schirmer M et al. (2006) Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations. |
43. |
Ekroos M et al. (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4. |
44. |
van Herwaarden AE et al. (2007) Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. |
45. |
Idle JR et al. (2000) Medical implications of HGP's sequence of chromosome 22. |
46. |
Nakamura K et al. (2002) CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability. |
47. |
Nelson DR et al. (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. |
48. |
Gasche Y et al. (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. |
49. |
Gaedigk A et al. (1991) Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. |
50. |
Koren G et al. (2006) Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. |
51. |
Desmeules J et al. (1991) Impact of environmental and genetic factors on codeine analgesia. |
52. |
Gough AC et al. (1990) Identification of the primary gene defect at the cytochrome P450 CYP2D locus. |
55. |
Chen X et al. (1995) The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease. |
56. |
Johansson I et al. (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. |
57. |
Panserat S et al. (1994) DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers. |
58. |
Saxena R et al. (1994) Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. |
59. |
Broly F et al. (1995) A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency. |
60. |
Steen VM et al. (1995) Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene. |
61. |
Marez D et al. (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. |
63. |
Vistisen K et al. (1992) Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. |
64. |
Ikeya K et al. (1989) Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. |
66. |
Sesardic D et al. (1988) A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. |
67. |
Guengerich FP et al. (1986) Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation. |
68. |
None (1967) Acetophenetidin sensitivity. |
69. |
Devonshire HW et al. (1983) The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition. |
71. |
Schweikl H et al. (1993) Expression of CYP1A1 and CYP1A2 genes in human liver. |
72. |
Liang HC et al. (1996) Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism. |
73. |
Buters JT et al. (1996) Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2. |
74. |
Nakajima M et al. (1999) Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. |
75. |
Sachse C et al. (1999) Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. |
76. |
Tantcheva-Poór I et al. (1999) Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. |
77. |
Christiansen L et al. (2000) Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda. |
78. |
Rasmussen BB et al. (2002) The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. |
79. |
Wooding SP et al. (2002) DNA sequence variation in a 3.7-kb noncoding sequence 5' of the CYP1A2 gene: implications for human population history and natural selection. |
80. |
Browning SL et al. (2010) CYP1A2 is more variable than previously thought: a genomic biography of the gene behind the human drug-metabolizing enzyme. |
81. |
Thum T et al. (2000) Gene expression in distinct regions of the heart. |
82. |
Lessard E et al. (1997) Role of CYP2D6 in the N-hydroxylation of procainamide. |
83. |
Lessard E et al. (1999) Involvement of CYP2D6 activity in the N-oxidation of procainamide in man. |
84. |
Tucker GT et al. (1977) Polymorphic hydroxylation of debrisoquine. |
85. |
Heim MH et al. (1992) Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. |
86. |
Heim M et al. (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. |
87. |
Kimura S et al. (1989) The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. |
88. |
Matsunaga E et al. (1989) The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats. |
89. |
Skoda RC et al. (1988) Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. |
90. |
Gonzalez FJ et al. (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. |
91. |
Gonzalez FJ et al. (1988) Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. |
92. |
Eichelbaum M et al. (1987) Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. |
93. |
Gonzalez FJ et al. (1987) Debrisoquine 4-hydroxylase: characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism. |
94. |
Harmer D et al. (1986) The relationship between the acetylator and the sparteine hydroxylation polymorphisms. |
95. |
Eichelbaum M et al. (1986) The genetic polymorphism of sparteine metabolism. |
96. |
Nebert DW et al. (1987) The P450 gene superfamily: recommended nomenclature. |
97. |
Eichelbaum M et al. (1985) Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans. |
98. |
Distlerath LM et al. (1984) Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme. |
99. |
Dahl ML et al. (1995) Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. |
100. |
Agúndez JA et al. (1995) Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. |
101. |
Mura C et al. (1993) DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers. |
103. |
Bertilsson L et al. (1993) Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. |
104. |
Gough AC et al. (1993) Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis. |
105. |
Daly AK et al. (1996) Nomenclature for human CYP2D6 alleles. |
106. |
Nelson DR et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. |
107. |
None (1997) Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? |
108. |
Sachse C et al. (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. |
109. |
McLellan RA et al. (1997) Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. |
110. |
Tyndale RF et al. (1997) Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. |
111. |
Mikus G et al. (1998) Relevance of deficient CYP2D6 in opiate dependence. |
112. |
Lundqvist E et al. (1999) Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. |
114. |
Tateishi T et al. (1999) Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. |
115. |
Brown MA et al. (2000) Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. |
116. |
Payami H et al. (2001) Parkinson's disease, CYP2D6 polymorphism, and age. |
117. |
Elbaz A et al. (2004) CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. |
118. |
Deng Y et al. (2004) Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease. |
119. |
Liou YH et al. (2006) The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population. |
120. |
Pilotto A et al. (2009) Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. |
121. |
Schroth W et al. (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. |